Madrigal Pharmaceuticals vs Mirum Pharmaceuticals
MDGL and MIRM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDGL and MIRM compare
Madrigal Pharmaceuticals is the larger company, worth 1.8 times as much as Mirum Pharmaceuticals ($9.9B against $5.5B).
Madrigal Pharmaceuticals grew revenue faster over the last twelve months (149% versus 44.0% for Mirum Pharmaceuticals).
Madrigal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −25.3% compared with −139% at Mirum Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDGL | MIRM |
|---|---|---|
| Size and price | ||
| Market cap | $9.9B | $5.5B |
| Share price | $430.36 | $85.00 |
| Change, 1 year | 2.1% | 20.6% |
| Change, 5 years | 363% | 424% |
| Beta (5Y) | 0.71 | 0.67 |
| Employees | 915 | 372 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 3 (better) |
| Performance score | 2 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 7.7× (better) | 8.9× |
| P/B | 19.0× | – |
| FCF yield | −2.1% (better) | −4.1% |
| Fair value | $232.20 | – |
| Margin of safety | −85.3% | – |
| Growth | ||
| Revenue growth (TTM) | 149% (better) | 44.0% |
| Profitability | ||
| Operating margin | −25.1% (better) | −135% |
| Net margin | −25.3% (better) | −139% |
| FCF margin | −16.1% (better) | −37.0% |
| Return on equity | −53.3% (better) | −703% |
| Return on invested capital | −1338% | – |
| Financial health | ||
| Debt / equity | 0.65 | – |
| Interest coverage | −10.2× (better) | −62.1× |
| Current ratio | 3.20 (better) | 2.86 |
| Altman Z-score | 6.72 (better) | −0.47 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 110% |
| Held by insiders | 24.3% | 9.2% |
| Insider net buying, 12 months | −$81.5M | −$33.2M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 13.7% | 11.8% |
Go deeper
- MDGL stock overview
- MDGL income statement
- MDGL valuation and score
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.